Teva Pharmaceutical Industries Limited (TEVJF)
OTCMKTS · Delayed Price · Currency is USD
28.36
-4.48 (-13.64%)
At close: Jan 26, 2026
Teva Pharmaceutical Industries Employees
As of December 31, 2025, Teva Pharmaceutical Industries had 32,842 total employees, including 31,173 full-time and 1,669 part-time employees. The number of employees decreased by 2,844 or -7.97% compared to the previous year.
Employees
32,842
Change (1Y)
-2,844
Growth (1Y)
-7.97%
Revenue / Employee
$539,178
Profits / Employee
$44,051
Market Cap
39.16B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 32,842 | -2,844 | -7.97% | 31,173 | 1,669 |
| Dec 31, 2024 | 35,686 | -786 | -2.16% | 33,892 | 1,794 |
| Dec 31, 2023 | 36,472 | 1,347 | 3.83% | 35,001 | 1,471 |
| Dec 31, 2022 | 35,125 | -854 | -2.37% | 34,004 | 1,121 |
| Dec 31, 2021 | 35,979 | -2,393 | -6.24% | 34,713 | 1,266 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Jushi Holdings | 1,234 |
| MariMed | 832 |
| Glass House Brands | 374 |
| Earth Science Tech | 76 |
| Elite Pharmaceuticals | 68 |
| Radnostix | 42 |
| Healthy Extracts | 2 |
Teva Pharmaceutical Industries News
- 1 day ago - Teva to Present at the Upcoming Investor Conferences in March - GlobeNewsWire
- 3 days ago - FDA Accepts Teva's New Long-Acting Schizophrenia Treatment Application - Benzinga
- 4 days ago - Teva (TEVA) Advances Schizophrenia Treatment with FDA Application - GuruFocus
- 5 days ago - Teva, Medincell granted FDA review for long-acting antipsychotic - Seeking Alpha
- 5 days ago - FDA Accepts NDA For Teva And Medincell's Olanzapine LAI In Schizophrenia Treatment - Nasdaq
- 5 days ago - Teva (TEVA) Gains FDA Nod for Schizophrenia Treatment Application - GuruFocus
- 5 days ago - U.S. Food and Drug Administration (FDA) Accepts Teva's New Drug Application (NDA) for Olanzapine Extended-Release Injectable Suspension (TEV-'749) for the Once-Monthly Treatment of Schizophrenia in Adults - GlobeNewsWire
- 5 days ago - Price Over Earnings Overview: Teva Pharmaceutical Indus - Benzinga